Background: Despite the development of targeted therapies for pulmonary arterial hypertension (PAH), some patients fail to respond to medical therapy. There are a number of types of PAH, one of which is pulmonary venoocclusive disease (PVOD). Unlike other PAH types, the hallmark pathology of PVOD is fibrous occlusion of the small venules, potentially with arterial involvement. It was hypothesized that a lack of response to medical therapy in clinically diagnosed PAH can be explained by misdiagnosed PVOD.
Methods: This study reviewed cases of 14 patients with clinically diagnosed PAH who had failed to respond to medical therapy and had lung tissue available from autopsy or explant. Control samples (n = 6) were obtained from lungs explanted for other causes, and a previous transthoracic echocardiogram excluded pulmonary hypertension. Comprehensive vessel morphometry was performed, and the clinical data reviewed.
Results: Vessel analysis confirmed 86% of case patients had PVOD and 14% had arterial-only PAH (artPAH). In the PVOD case patients, significant pathology was present in all vessel types with similar obstructive, intimal fibrosis in the venules (p < 0.0001) and arterioles (p < 0.0001). This was considerably different from the intimal concentric laminar smooth muscle proliferation in the artPAH cases. There were no significant differences in clinical presentation between PVOD and artPAH case patients. Pulmonary edema was not observed in the PVOD cases.
Conclusions: PVOD is an underdiagnosed and commonly misdiagnosed cause of pulmonary hypertension, which may present with a failure to respond to medical therapy. Further studies on PVOD may help confirm whether a change in its classification as a type of PAH is necessary.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1378/chest.08-2006 | DOI Listing |
Cancer Treat Rev
January 2025
Gastrointestinal Unit, Department of Medicine, Royal Marsden Hospital, London and Surrey, UK. Electronic address:
Claudins (CLDNs) play a crucial and indispensable role as fundamental components within the structure of tight junctions. Due to the distinct and unique distribution pattern exhibited by CLDNs in both normal and malignant tissues, these proteins have garnered significant attention as pivotal targets for systemic anti-cancer therapy and as noteworthy diagnostic markers. This review provides a comprehensive and detailed elucidation of the fundamental understanding surrounding CLDNs, their intricate expression patterns, the potential role they play in cancer diagnosis and therapeutic potentials; all encapsulated within a succinct summary of the cutting-edge advancements and the information derived from various clinical trials.
View Article and Find Full Text PDFJ Neurol Sci
January 2025
The Gaffin Center for Neuro-Oncology, Sharett Institute of Oncology, Hadassah Medical Center, and Faculty of Medicine, The Hebrew University of Jerusalem, Israel. Electronic address:
Introduction: Herpes encephalitis is known to affect patients undergoing brain radiotherapy, but early diagnosis and treatment, the foremost determinants of disease outcome, remain challenging in this patient population. This can be due to attribution of symptoms to the brain tumor and radiation side effects, as well as patients' atypical clinical presentation. Here we sought to highlight pearls and pitfalls in the clinical course and diagnostic workup which may facilitate timely diagnosis and improve disease outcome.
View Article and Find Full Text PDFDis Colon Rectum
February 2025
Department of Colorectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Ohio.
Background: Patients with Crohn's disease face an elevated risk of colorectal cancer, in part due to underlying chronic inflammation. Biologic therapy is the mainstay of medical treatment; however, the impact of treatment on colorectal cancer-related outcomes remains unclear.
Objective: To investigate the association between prior exposure to biologic treatment and colorectal cancer-related outcomes in patients with underlying Crohn's disease.
Am J Manag Care
January 2025
McGovern Medical School at UTHealth Houston, 4513 Teas St, Bellaire, TX 77401.
Objective: To examine the effect of physiologic insulin resensitization (PIR) on the cost of treating patients with diabetes and chronic kidney disease (CKD).
Study Design: The mean 1-year cost of treating 66 Medicare Advantage patients with diabetes and CKD who were receiving PIR was compared with that of treating 1301 Medicare Advantage patients with diabetes and CKD not receiving PIR. Differences in disease severity were compared using mean risk adjustment factor scores.
Am J Manag Care
January 2025
Arine, 595 Market St #2550, San Francisco, CA 94105. Email:
Objective: To assess the effects of a nurse-led personalized care plan on the duration of olaparib therapy among patients with cancer.
Study Design: Cohort study conducted from January 2020 to June 2022.
Methods: Data from an independent specialty pharmacy were used to identify patients 18 years and older with at least 1 olaparib (Lynparza) prescription who were at high risk for olaparib nonadherence as assessed using a pharmacy intake survey.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!